Viralytics meets primary goal of melanoma trial
19 September, 2013 by Dylan Bushell-EmblingA phase II trial of Viralytics' (ASX:VLA) Cavatak cancer-targeting virus in late-stage melanoma is still recruiting patients but has already met its primary endpoint.
New government, no science portfolio
17 September, 2013The incoming ministry for the newly elected Australian Government has been unveiled.
Patrys antibody gets orphan drug status in myeloma
12 September, 2013 by Dylan Bushell-EmblingPatrys's (ASX:PAB) anticancer antibody, PAT-SM6, has been granted orphan drug designation in the EU for bone marrow cancer multiple myeloma.
Viralytics cleared to begin UK cancer trial
11 September, 2013 by Dylan Bushell-EmblingThe UK's MHRA has given its final approval for a phase I/II study of Viralytics' oncolytic virus in melanoma, prostate, lung or metastatic bladder cancers.
Starpharma developing new chemotherapy formulation
11 September, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) will advance dendrimer-oxaliplatin into development, after lab trials indicate its version of the chemotherapy drug can be more effective and reduces toxicity.
ResMed completes recruitment for heart failure trial
06 September, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has signed up all 1325 patients for what it is billing as the world's largest study of sleep-disordered breathing therapy in at-risk heart failure patients.
A new CEO for Dendright
05 September, 2013Brisbane-based biotech Dendright has appointed Helen Roberts as CEO.
Telesso to raise $6.5m to fund acne drug trial
04 September, 2013 by Dylan Bushell-EmblingShell company Telesso (ASX:TEO) aims to raise up to $6.5m to help support its plan to acquire Mimetica, take on the company's name and fund phase II trials for Mimetica's acne drug candidate.
GI Dynamics extends Australian reach of EndoBarrier
03 September, 2013 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) said five new centres in Australian capital cities have agreed to offer EndoBarrier as a treatment option for type 2 diabetes and obesity.
GTG signs with new US PPO for BREVAGen
22 August, 2013Genetic Technologies (ASX:GTG) has arranged for insurance claims for its BREVAGen breast cancer risk test to be adjudicated in-network with an eighth US PPO.
Prima cleared to extend cancer trial to Korea
22 August, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has received approval to extend its CANVAS cancer vaccine study to South Korea, the first Asian country to be involved in the phase II/III trial.
Ascend gears up for cancer immunotherapy trials
22 August, 2013 by Dylan Bushell-EmblingAscend Biopharmaceuticals CEO Clement Leong details the company’s plans for Australian clinical trials of its key products, a cancer vaccine and an oncolytic virus.
Sitting too much?
22 August, 2013Findings of the 12-year AusDiab follow-up study show that Australians aren’t making the lifestyle changes needed to address obesity, high blood pressure and diabetes.
Trials in autoimmune disease
21 August, 2013 by Susan WilliamsonGiving children their own cord blood to prevent them getting type 1 diabetes and development of a new immunotherapy are part of a more tailored approach to treating autoimmune diseases.
Innovation fund for health and medical research
20 August, 2013The Australian Government has committed to growing investment in the health and medical research sector with the Medical Research Innovation Fund.
